Literature DB >> 16614625

The safety of psychotropic drug use during pregnancy: a review.

Adrienne Einarson1.   

Abstract

A substantial number of women of childbearing age are prescribed psychotropic drugs, and because nearly 50% of pregnancies are unplanned, many women are still taking them upon becoming pregnant. This article reviews the various classes of psychotropic drugs that are commonly used to treat psychiatric disorders--antidepressants, benzodiazepines, antipsychotics, antiepileptics, lithium and monoamine oxidase (MAO) inhibitors--in terms of their safety during pregnancy. Evidence-based information from epidemiologic studies indicates that most psychotropic drugs are relatively safe for use during pregnancy. There is also an increasingly large body of evidence-based information in the literature indicating that it may be more harmful to both the mother and her baby if she is not treated appropriately when suffering from a severe psychiatric disorder. Therefore, it is important for women with psychiatric disorders and their healthcare providers to have access to evidenced-based information about the safety of these drugs when taken during pregnancy to ensure that women make an informed decision as to whether they should continue with the pharmacotherapy they have been using to treat their condition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16614625

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  2 in total

1.  Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxiety.

Authors:  Tiffany Behringer; Bruce L Rollman; Bea Herbeck-Belnap; Patricia R Houck; Sati Mazumdar; Eleanor Bimla Schwarz
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 2.  Psychopharmacoteratophobia: Excessive fear of malformation associated with prescribing psychotropic drugs during pregnancy: An Indian perspective.

Authors:  Dushad Ram; Basavnna Gowdappa; H G Ashoka; Najla Eiman
Journal:  Indian J Pharmacol       Date:  2015 Sep-Oct       Impact factor: 1.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.